NCT05299749 Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory Hallucinations
| NCT ID | NCT05299749 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Boston VA Research Institute, Inc. |
| Condition | Schizophrenia |
| Study Type | INTERVENTIONAL |
| Enrollment | 104 participants |
| Start Date | 2022-03-01 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 104 participants in total. It began in 2022-03-01 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Neurofeedback intervention aimed to regulate the superior temporal gyrus (STG) activation and default mode network (DMN) connectivity as well as to reduce the auditory hallucinations (AH) schizophrenia patients with medication resistant AH.
Eligibility Criteria
Inclusion Criteria: * patients diagnosed with SZ or schizoaffective disorder using DSM-5 criteria * auditory hallucinations not responsive to pharmacology as determined by chart review and a clinical interview of SCID. Exclusion Criteria: * neurologic illness * major head trauma * electroconvulsive therapy * alcohol or drug dependence * alcohol or drug abuse within the past five years * verbal IQ below 70
Contact & Investigator
margaret niznikiewicz
PRINCIPAL INVESTIGATOR
Boston VA Research Institute, Inc.
Frequently Asked Questions
Who can join the NCT05299749 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying Schizophrenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05299749 currently recruiting?
Yes, NCT05299749 is actively recruiting participants. Contact the research team at margaret_niznikiewicz@hms.harvard.edu for enrollment information.
Where is the NCT05299749 trial being conducted?
This trial is being conducted at Brockton, United States.
Who is sponsoring the NCT05299749 clinical trial?
NCT05299749 is sponsored by Boston VA Research Institute, Inc.. The principal investigator is margaret niznikiewicz at Boston VA Research Institute, Inc.. The trial plans to enroll 104 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.